Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1200 of 3284 entries
View as:

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Phase: N/A Priority: Normal
NCT ID: NCT07038928 Org: User:
Start: 06/30/25 End: 12/31/26 Due: 12/31/27

European Study of Cardiovascular Risk

Phase: N/A Priority: Normal
NCT ID: NCT00882336 Org: User:
Start: 05/31/09 End: 10/31/09 Due: 10/31/10

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00829127 Org: User:
Start: 01/31/09 End: 01/31/09 Due: 01/31/10

Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia

Phase: N/A Priority: Normal
NCT ID: NCT00984529 Org: User:
Start: 09/30/09 End: 02/28/10 Due: 02/28/11

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01068717 Org: User:
Start: 03/31/10 End: 03/31/10 Due: 03/31/11

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT06299826 Org: User:
Start: 06/04/24 End: 02/24/26 Due: 02/24/27

Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland

Phase: N/A Priority: Normal
NCT ID: NCT00681382 Org: User:
Start: 10/31/06 End: 04/30/07 Due: 04/30/08

Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

Phase: N/A Priority: Normal
NCT ID: NCT01219114 Org: User:
Start: 10/31/10 End: 11/30/13 Due: 11/30/14

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Phase: N/A Priority: Normal
NCT ID: NCT05219162 Org: User:
Start: 02/25/22 End: 05/09/24 Due: 05/09/25

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Phase: N/A Priority: Normal
NCT ID: NCT06268873 Org: User:
Start: 03/29/24 End: 12/09/27 Due: 12/09/28

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Phase: N/A Priority: Normal
NCT ID: NCT06386263 Org: User:
Start: 04/22/24 End: 12/08/25 Due: 12/08/26

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Phase: N/A Priority: Normal
NCT ID: NCT00681369 Org: User:
Start: 05/31/07 End: 06/30/07 Due: 06/30/08

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase: N/A Priority: Normal
NCT ID: NCT03003962 Org: User:
Start: 01/02/17 End: 06/30/26 Due: 06/30/27

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Phase: N/A Priority: Normal
NCT ID: NCT01305551 Org: User:
Start: 03/31/11 End: 03/31/11 Due: 03/31/12

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06194448 Org: User:
Start: 04/21/24 End: 03/31/28 Due: 03/31/29

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT07008963 Org: User:
Start: 06/16/25 End: 06/19/25 Due: 06/19/26

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

Phase: N/A Priority: Normal
NCT ID: NCT07007793 Org: User:
Start: 08/07/25 End: 02/18/28 Due: 02/18/29

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

Phase: N/A Priority: Normal
NCT ID: NCT03813407 Org: User:
Start: 04/02/19 End: 06/29/26 Due: 06/29/27

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels

Phase: N/A Priority: Normal
NCT ID: NCT06980428 Org: User:
Start: 05/27/25 End: 12/04/26 Due: 12/04/27

A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab

Phase: N/A Priority: Normal
NCT ID: NCT04884269 Org: User:
Start: 08/11/21 End: 03/03/23 Due: 03/03/24

Study of AZD8931 in Patients With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00637039 Org: User:
Start: 02/29/08 End: 12/31/12 Due: 12/31/13

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01340040 Org: User:
Start: 07/31/11 End: 05/31/12 Due: 05/31/13

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

Phase: N/A Priority: Normal
NCT ID: NCT07029737 Org: User:
Start: 06/15/25 End: 12/15/28 Due: 12/15/29

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

Phase: N/A Priority: Normal
NCT ID: NCT01000740 Org: User:
Start: 08/31/09 End: 04/30/10 Due: 04/30/11

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00747175 Org: User:
Start: 08/31/08 End: 04/30/09 Due: 04/30/10